RTID-08. A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA (ndGBM OR rGBM)

BACKGROUND: GBM is the most common and most aggressive primary brain tumor with poor prognosis and median overall survival (mOS) of patients with ndGBM and rGBM being 15 vs 5-7 months, respectively. Selinexor is a first-in class, oral, selective nuclear export inhibitor which forces nuclear retentio...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Wen, Patrick, Odia, Yazmin, Mehta, Minesh, Goldlust, Samuel, Tamir, Sharon, Shacham, Sharon, Wang, Hongwei, Sheehan, Heidi, Li, Kai
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2020
Konular:
Randomized Trials in Development
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651017/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.813
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller